Chevy Chase Trust Holdings Inc. boosted its holdings in Quest Diagnostics Inc (NYSE:DGX) by 1.0% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 119,506 shares of the medical research company’s stock after acquiring an additional 1,141 shares during the period. Chevy Chase Trust Holdings Inc. owned 0.09% of Quest Diagnostics worth $11,190,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also modified their holdings of the stock. Oppenheimer Asset Management Inc. grew its stake in Quest Diagnostics by 732.3% in the 3rd quarter. Oppenheimer Asset Management Inc. now owns 4,303 shares of the medical research company’s stock valued at $402,000 after acquiring an additional 3,786 shares during the last quarter. Asset Management One Co. Ltd. grew its stake in Quest Diagnostics by 23.7% in the 3rd quarter. Asset Management One Co. Ltd. now owns 271,647 shares of the medical research company’s stock valued at $25,329,000 after acquiring an additional 51,964 shares during the last quarter. BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp grew its stake in Quest Diagnostics by 8.4% in the 3rd quarter. BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp now owns 77,175 shares of the medical research company’s stock valued at $7,227,000 after acquiring an additional 6,000 shares during the last quarter. Allianz Asset Management GmbH grew its stake in Quest Diagnostics by 10.5% in the 3rd quarter. Allianz Asset Management GmbH now owns 2,033,496 shares of the medical research company’s stock valued at $190,417,000 after acquiring an additional 193,829 shares during the last quarter. Finally, Caisse DE Depot ET Placement DU Quebec grew its stake in Quest Diagnostics by 106.0% in the 3rd quarter. Caisse DE Depot ET Placement DU Quebec now owns 58,700 shares of the medical research company’s stock valued at $5,520,000 after acquiring an additional 30,200 shares during the last quarter. 89.20% of the stock is currently owned by hedge funds and other institutional investors.

Quest Diagnostics Inc (NYSE:DGX) opened at $97.14 on Thursday. The firm has a market cap of $13,240.00, a PE ratio of 17.39, a PEG ratio of 2.02 and a beta of 0.60. Quest Diagnostics Inc has a 1-year low of $90.10 and a 1-year high of $112.96. The company has a current ratio of 1.47, a quick ratio of 1.37 and a debt-to-equity ratio of 0.78.

Quest Diagnostics (NYSE:DGX) last announced its quarterly earnings data on Thursday, October 19th. The medical research company reported $1.39 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $1.35 by $0.04. The business had revenue of $1.93 billion for the quarter, compared to analyst estimates of $1.92 billion. Quest Diagnostics had a net margin of 8.82% and a return on equity of 15.53%. The company’s revenue was up 2.4% on a year-over-year basis. During the same period in the prior year, the firm posted $1.37 EPS. research analysts anticipate that Quest Diagnostics Inc will post 5.65 earnings per share for the current year.

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, January 24th. Investors of record on Tuesday, January 9th will be issued a $0.45 dividend. The ex-dividend date of this dividend is Monday, January 8th. This represents a $1.80 annualized dividend and a yield of 1.85%. Quest Diagnostics’s payout ratio is 37.50%.

A number of equities research analysts recently commented on the stock. Jefferies Group set a $98.00 price objective on shares of Quest Diagnostics and gave the company a “hold” rating in a research note on Saturday, November 25th. Zacks Investment Research raised shares of Quest Diagnostics from a “sell” rating to a “hold” rating in a research note on Monday, November 6th. KeyCorp reaffirmed a “hold” rating on shares of Quest Diagnostics in a research note on Friday, October 27th. Canaccord Genuity raised their price target on shares of Quest Diagnostics from $100.00 to $105.00 and gave the stock a “buy” rating in a research note on Thursday, October 26th. Finally, Wells Fargo & Company decreased their price target on shares of Quest Diagnostics from $88.00 to $86.00 and set a “market perform” rating on the stock in a research note on Friday, October 20th. One research analyst has rated the stock with a sell rating, fifteen have issued a hold rating and seven have given a buy rating to the stock. The stock presently has a consensus rating of “Hold” and a consensus target price of $106.28.

TRADEMARK VIOLATION NOTICE: “Chevy Chase Trust Holdings Inc. Raises Position in Quest Diagnostics Inc (DGX)” was first reported by Watch List News and is the property of of Watch List News. If you are viewing this article on another domain, it was stolen and reposted in violation of U.S. and international trademark and copyright laws. The correct version of this article can be viewed at https://www.watchlistnews.com/chevy-chase-trust-holdings-inc-raises-position-in-quest-diagnostics-inc-dgx/1763398.html.

Quest Diagnostics Profile

Quest Diagnostics Incorporated is a provider of diagnostic information services. The Company operates through two businesses: Diagnostic Information Services and Diagnostic Solutions. The Diagnostic Information Services business develops and delivers diagnostic testing information and services, providing insights that empower and enable a range of customers, including patients, clinicians, hospitals, integrated delivery networks (IDNs), health plans, employers and accountable care organizations (ACOs).

Want to see what other hedge funds are holding DGX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Quest Diagnostics Inc (NYSE:DGX).

Institutional Ownership by Quarter for Quest Diagnostics (NYSE:DGX)

Receive News & Ratings for Quest Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quest Diagnostics and related companies with Analyst Ratings Network's FREE daily email newsletter.